Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H J Sutherland

Showing results (91-100 of 101) with videos related to

Pageof 11
Sort By:
Bone Marrow Transplantation|March 29, 2000
Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemiaC L Toze, J D Shepherd, J M Connors, et al.
Leukemia & Lymphoma|August 23, 2006
Leukocyte count as a predictor of death during remission induction in acute myeloid leukemiaM J Greenwood, M D Seftel, C Richardson, et al.
Bone Marrow Transplantation|July 15, 2009
Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimensY R Abou-Mourad, B C Lau, M J Barnett, et al.
Bone Marrow Transplantation|October 17, 2003
Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysisD L Forrest, T J Nevill, S C Naiman, et al.
Blood|September 10, 1998
Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantationT J Nevill, H C Fung, J D Shepherd, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2000
Allografting for indolent lymphoid neoplasmsC L Toze, J D Shepherd, J M Connors, et al.
Bone Marrow Transplantation|June 26, 1999
Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's diseaseD E Reece, T J Nevill, A Sayegh, et al.
Bone Marrow Transplantation|August 6, 2008
Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AMLT J Nevill, D E Hogge, C L Toze, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2006
Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomesK W Song, M J Barnett, R D Gascoyne, et al.
Bone Marrow Transplantation|September 10, 2005
Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host diseaseC L Toze, A Galal, M J Barnett, et al.
Pageof 11

Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
Bone Marrow Transplantation|March 29, 2000
Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemiaC L Toze, J D Shepherd, J M Connors, et al.
Leukemia & Lymphoma|August 23, 2006
Leukocyte count as a predictor of death during remission induction in acute myeloid leukemiaM J Greenwood, M D Seftel, C Richardson, et al.
Bone Marrow Transplantation|July 15, 2009
Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimensY R Abou-Mourad, B C Lau, M J Barnett, et al.
Bone Marrow Transplantation|October 17, 2003
Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysisD L Forrest, T J Nevill, S C Naiman, et al.
Blood|September 10, 1998
Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantationT J Nevill, H C Fung, J D Shepherd, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2000
Allografting for indolent lymphoid neoplasmsC L Toze, J D Shepherd, J M Connors, et al.
Bone Marrow Transplantation|June 26, 1999
Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's diseaseD E Reece, T J Nevill, A Sayegh, et al.
Bone Marrow Transplantation|August 6, 2008
Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AMLT J Nevill, D E Hogge, C L Toze, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2006
Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomesK W Song, M J Barnett, R D Gascoyne, et al.
Bone Marrow Transplantation|September 10, 2005
Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host diseaseC L Toze, A Galal, M J Barnett, et al.
Pageof 11